Pure Global AI
NCT06055660Completed

Moesin Expression in Clear Cell Renal Cell Carcinoma

Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.
Sohag UniversityClinicalTrials.govgenetic
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
Study type
Observational
Intervention type
genetic
Sponsor & location
Primary sponsor
Sohag University
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2017
End date
Dec 31, 2021
Enrollment
50 participants
Primary outcome

Detection of Moesin in renal cell carcinoma

Summary

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are
 several histological variants of RCC that are associated with variable prognostic outcomes.
 Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire
 some mesenchymal criteria as enhanced invasive potential. There are several cell surface
 molecules that are implicated in EMT. Moesin is one of these molecules that is involved in
 EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting
 Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with
 RCC.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06055660
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06055660 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Completed. The study focuses on Renal Cell Carcinoma. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.